Praluent vs Lisinopril: What to Do When One Fails

Why These Two Drugs Are Not Interchangeable

Alirocumab and lisinopril occupy completely different positions on the cardiometabolic risk map. One targets circulating LDL cholesterol through a biologic mechanism; the other controls arterial blood pressure through a small-molecule enzyme inhibitor. Asking whether to switch from one to the other is like asking whether to swap a cholesterol panel for a blood pressure cuff. Both matter, but they answer separate questions.

Different Mechanisms, Different Failure Modes

Alirocumab (Praluent) is a fully human monoclonal antibody that binds PCSK9, the protein that degrades LDL receptors on hepatocytes. By neutralizing PCSK9, alirocumab allows LDL receptors to recycle, pulling more LDL-C out of circulation. In ODYSSEY OUTCOMES (N=18,924), alirocumab 75 to 150 mg every 2 weeks reduced LDL-C by approximately 54.7% from baseline compared with placebo, and cut the composite of coronary heart disease death, nonfatal MI, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization by 15% (hazard ratio 0.85, 95% CI 0.78 to 0.93, P<0.001) [1].

Lisinopril belongs to the ACE-inhibitor class. It blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone release. The result is lower systemic vascular resistance and, in most patients, a 10 to 15 mmHg drop in systolic blood pressure at standard doses of 10 to 40 mg daily. In ALLHAT (N=33,357), lisinopril produced outcomes equivalent to chlorthalidone for the primary composite of fatal coronary heart disease and nonfatal MI (relative risk 1.00, 95% CI 0.94 to 1.07) [2].

Neither drug can substitute for the other. An ACE inhibitor will not lower LDL-C. A PCSK9 inhibitor will not reduce blood pressure.

The Question Behind "One Fails"

When a clinician or patient asks what to do when one of these drugs fails, the real question is almost always one of two things. Either the lipid target has not been reached despite what appeared to be adequate therapy, or blood pressure control has been lost or was never achieved. Those are distinct clinical scenarios requiring distinct responses.

When Alirocumab (Praluent) Fails

Alirocumab "fails" in one of three situations: LDL-C remains above goal despite correct dosing, the patient cannot tolerate the injection, or cost or access creates a practical barrier to continued therapy.

LDL Target Not Reached

The 2022 ACC/AHA guideline on cardiovascular risk reduction recommends an LDL-C target of <70 mg/dL for very-high-risk patients and <55 mg/dL for some with established atherosclerotic cardiovascular disease (ASCVD) [see ACC/AHA 2022 Guideline, American College of Cardiology]. If a patient on alirocumab 150 mg every 2 weeks still does not reach goal, the first step is to verify adherence and injection technique, then confirm the patient is also on maximally tolerated statin therapy. PCSK9 inhibitors produce the largest absolute LDL-C reductions when combined with a high-intensity statin such as rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg daily [1].

If statin plus alirocumab is still insufficient, the next addition is ezetimibe 10 mg daily, which inhibits intestinal cholesterol absorption and can contribute an additional 18 to 23% LDL-C reduction. That three-drug regimen, high-intensity statin plus ezetimibe plus PCSK9 inhibitor, represents the practical ceiling of oral and injectable lipid-lowering therapy available outside clinical trials.

Inclisiran, a small interfering RNA that silences PCSK9 synthesis and is dosed only twice yearly after the initial loading doses, may be substituted for alirocumab in patients with adherence challenges to biweekly injections. The ORION-10 trial (N=1,561) showed inclisiran 284 mg reduced LDL-C by 52.3% versus placebo at day 510 (P<0.001) [3].

Injection-Site Reactions and Tolerability

Injection-site reactions occur in about 7% of patients on alirocumab versus 5% on placebo in pooled ODYSSEY trial data [1]. Rotating injection sites to the abdomen, thigh, or upper arm typically resolves mild reactions. Persistent or severe reactions warrant switching to evolocumab (Repatha), the other approved PCSK9 inhibitor in the same drug class, rather than abandoning PCSK9 inhibition entirely.

Cost and Access Failure

At a list price near $6,000 annually before rebates, alirocumab is inaccessible for many patients without strong insurance coverage. Sanofi's patient assistance program (Praluent Together) covers eligible uninsured or underinsured patients. When access cannot be secured, bempedoic acid (Nexletol) 180 mg once daily, an ATP-citrate lyase inhibitor, provides an additional 18 to 22% LDL-C reduction on top of statin or as monotherapy in statin-intolerant patients, and carries a substantially lower cost [4].

Alirocumab failure decision framework:

| Failure Type | First Step | Second Step | |---|---|---| | LDL above goal on 150 mg q2w | Confirm statin co-therapy at max tolerated dose | Add ezetimibe 10 mg daily; consider inclisiran | | Injection intolerance | Rotate sites; try pre-filled syringe auto-injector | Switch to evolocumab 140 mg q2w | | Cost or access barrier | Enroll in Praluent Together assistance program | Switch to bempedoic acid or inclisiran based on payer coverage | | LDL still above <55 mg/dL goal on triple therapy | Refer to lipid specialist | Consider lomitapide or mipomersen in homozygous FH |

When Lisinopril Fails

Lisinopril "fails" when blood pressure remains above the guideline threshold despite adequate dosing, when the patient develops intolerable side effects, or when the drug is contraindicated by a new clinical development.

Blood Pressure Not Controlled

The JNC 8 algorithm and the 2017 ACC/AHA Hypertension Guidelines both acknowledge that many patients require two or more agents to reach a systolic BP target of <130 mmHg. If lisinopril 40 mg daily (the approved ceiling) does not reach goal, the standard next step is to add a calcium channel blocker (CCB) such as amlodipine 5 to 10 mg daily or a thiazide-type diuretic such as chlorthalidone 12.5 to 25 mg daily. ALLHAT demonstrated that chlorthalidone was numerically superior to lisinopril for preventing heart failure hospitalization (risk ratio 1.19, 95% CI 1.07 to 1.31) and stroke in Black patients [2], which informs which add-on to choose in those subgroups.

ACE-Inhibitor Cough

Lisinopril-induced cough affects 10 to 15% of patients overall, with rates closer to 30 to 40% in patients of East Asian descent. The mechanism involves bradykinin and substance P accumulation in the bronchial mucosa. This is a class-wide ACE-inhibitor effect, so substituting a different ACE inhibitor will not solve it.

The correct class switch is to an angiotensin receptor blocker (ARB). Losartan 50 to 100 mg, olmesartan 20 to 40 mg, and valsartan 80 to 320 mg all achieve comparable blood pressure reductions to lisinopril without the cough, because ARBs block angiotensin II at the receptor rather than inhibiting ACE. The ONTARGET trial (N=25,620) found that telmisartan was non-inferior to ramipril for the composite of cardiovascular death, MI, stroke, or heart failure hospitalization [5].

Hyperkalemia and Renal Impairment

Lisinopril reduces glomerular filtration pressure and can raise serum potassium, particularly in patients with CKD stage 3b or higher or in those already taking potassium-sparing diuretics. A serum potassium above 5.5 mEq/L on lisinopril warrants dose reduction or discontinuation. If the ACE inhibitor is being used for heart failure with reduced ejection fraction (HFrEF) or diabetic nephroprotection, the clinical team must weigh whether an ARB at a lower dose, or sacubitril/valsartan (Entresto) for HFrEF, can preserve organ protection without the hyperkalemia.

Bilateral renal artery stenosis is an absolute contraindication to ACE inhibitors and ARBs. When this diagnosis is confirmed, CCBs and beta-blockers become the primary antihypertensive agents.

Pregnancy and Contraindication

Lisinopril is contraindicated in pregnancy (FDA category D/X depending on trimester) due to fetal renal toxicity. Discovery of pregnancy in a patient on lisinopril requires immediate discontinuation and transition to a pregnancy-safe antihypertensive such as labetalol, nifedipine extended-release, or methyldopa per ACOG guidelines [6].

Using Both Drugs Simultaneously

Some patients carry both poorly controlled LDL-C and poorly controlled blood pressure. That patient population is common. The National Health and Nutrition Examination Survey data show approximately 48% of U.S. Adults have hypertension and nearly 12% have LDL-C above 160 mg/dL, with substantial overlap in those with established ASCVD [7].

No Pharmacokinetic Interaction

Alirocumab and lisinopril do not share metabolic pathways. Lisinopril is renally excreted unchanged; alirocumab is catabolized like other immunoglobulin G antibodies via proteolytic degradation. No dose adjustment of either drug is required when they are co-prescribed. The ACC/AHA 2019 primary prevention guideline supports concurrent use of lipid-lowering and antihypertensive therapy in patients with multiple cardiometabolic risk factors [8].

Additive Cardiovascular Risk Reduction

Each drug contributes independent, non-overlapping cardiovascular benefit. In ODYSSEY OUTCOMES, the absolute risk reduction with alirocumab was 1.6% over a median follow-up of 2.8 years in patients who had already suffered an acute coronary syndrome [1]. That is on top of background antihypertensive therapy that most participants were already receiving. Similarly, ALLHAT showed lisinopril's benefit accrues independently of lipid-lowering treatment status.

Combining both agents in a high-risk patient achieves risk reduction on two separate axes, LDL-C and blood pressure, that together account for the majority of attributable cardiovascular risk in the U.S. Population.

How to Decide Which Drug Needs Attention First

When a patient with both conditions presents with suboptimal control, prioritization depends on which abnormality carries more immediate risk.

Acute Risk Prioritization

A patient presenting within 12 months of an acute coronary syndrome (ACS) should have LDL-C addressed first and most aggressively. ODYSSEY OUTCOMES enrolled post-ACS patients and showed the greatest absolute benefit in those with baseline LDL-C at or above 100 mg/dL at the time of the ACS event [1]. Starting or intensifying alirocumab in that window produces measurable event reduction within months.

A patient presenting with a systolic BP above 160 mmHg requires immediate antihypertensive intervention. Uncontrolled severe hypertension carries short-term stroke risk that demands faster resolution than a lipid-lowering regimen can provide.

Shared Decision-Making Around Cost and Adherence

As the ACC/AHA 2022 cholesterol guideline notes, "clinician-patient discussion regarding the potential for ASCVD risk reduction, side effects, drug interactions, and patient preferences" should precede initiating a PCSK9 inhibitor [8]. That conversation must include a frank discussion of cost. A patient who cannot reliably afford alirocumab may achieve more durable LDL-C reduction with the combination of rosuvastatin 40 mg plus ezetimibe 10 mg, which together can lower LDL-C by 60 to 65% at a fraction of the cost.

Lisinopril, as a generic available for under $50 per year, almost never fails due to cost. Its tolerability challenges are the more common clinical hurdle.

Monitoring After a Therapy Change

Whether the change is from alirocumab to inclisiran, from lisinopril to an ARB, or the addition of a second antihypertensive agent, monitoring timelines are specific and non-negotiable.

Post-Change Lipid Monitoring

After initiating or switching a lipid-lowering agent, a fasting lipid panel should be checked at 4 to 12 weeks per the ACC/AHA guideline [8]. This confirms the new regimen is producing the expected response and gives early warning of non-adherence or inadequate response. For alirocumab, peak LDL-C lowering occurs within 4 weeks of the first injection.

Post-Change Blood Pressure Monitoring

After a change to antihypertensive therapy, blood pressure should be re-checked at 2 to 4 weeks, either in the office or via validated home blood pressure monitoring. The American Heart Association recommends home blood pressure monitoring with a cuff validated for accuracy, taken twice in the morning and twice in the evening for 7 consecutive days before the follow-up visit [9].

Serum potassium and creatinine should be checked 1 to 2 weeks after initiating or increasing any ACE inhibitor or ARB, particularly in patients with CKD or those on potassium supplements.

Real-World Adherence: Where Therapy Most Often Falls Short

Clinical trial results assume regular dosing. Real-world adherence to PCSK9 inhibitors at 12 months in U.S. Claims data is approximately 50 to 60%, substantially lower than the 90%+ adherence seen in ODYSSEY OUTCOMES [1]. Biweekly injection schedules and cost sharing are the main drivers of discontinuation. Inclisiran's twice-yearly dosing in a clinical setting removes the adherence variable almost entirely, since the healthcare provider administers the injection.

Lisinopril adherence in hypertension is similarly imperfect. A meta-analysis of 44 studies found that adherence to antihypertensive monotherapy at 12 months averages around 72% [10]. Cough is the most frequently cited reason for patient-initiated discontinuation.

Clinicians reviewing a patient with "failed" therapy should confirm actual adherence before escalating the drug regimen. A pill count, pharmacy refill history, or patient self-report with non-judgmental questioning is the required first diagnostic step before intensifying therapy.